CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Marijuana stocks have seen a surge of attention this year. Canaccord analyst Bobby Burleson said in a research note, “We believe his year’s midterms will reinforce the notion that cannabis in the U.S.has (passed) the tipping point on its way to eventual full legal status.”
On Wednesday Attorney General Jeff Sessions resigned from his position. This event has been well received by the public markets as many marijuana stocks have positively reacted to this news. Sessions, who has been a staunch adversary of the legalization of cannabis, took a very conservative approach when broaching the subject. Now that this has had time to resonate through the market, investors are looking ahead for new opportunity with pot stocks.
Three marijuana stocks to watch this week include Integrated Cannabis Company (ICNAF) (ICAN), Aphria (APHA) (APHQF) (APH) and Emerald Health Therapeutics (OTCQX: EMHTF) (TSX-V: EMH)
Integrated Cannabis Company (ICNAF) (ICAN) has seen its shares climb by roughly 50% over the last 2 months. On September 5, the opening price was $0.46 and Thursday saw shares of Integrated Cannabis Company (ICNAF) (ICAN) rallying to highs of $0.69.
Integrated Cannabis Company (ICNAF) (ICAN) currently has a product portfolio of CBD and THC oral sprays and has also begun expanding its offering for new products. In a recent announcement Integrated Cannabis Company (ICNAF) (ICAN) announced an agreement to license Cannabidiol (CBD) formulated gummies.
Integrated Cannabis plans to begin distributing CBD-based gummies through its contract manufacturer, Titration Technologies, in Phoenix, Arizona.
Integrated Cannabis Company (ICNAF) (ICAN) announced the completion of a Definitive Agreement to distribute its line of X-SPRAYS™ products through the clinic and doctors’ offices of Empower Clinics. Empower is a leading owner and operator of medical cannabis and wellness clinics in the US.
In addition to this, Integrated Cannabis Company (ICNAF) (ICAN) has also received its initial purchase order from Empower for a selection of X-SPRAYS™ products. Empower has more than 25,000 patients under care across 15 locations with medical cannabis treatments in Oregon, Washingtonand Illinois. The patient base in Oregon represents approximately one-third of the state’s total medical card issuance. In addition, Empower has an historical patient database of which exceeds 120,000 in the three States.
Aphria (NYSE: APHA) (TSX: APH) announced its proposed acquisition of CC Pharma GmbH, a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany. The transaction, when closed, will strengthen the Company’s end-to-end medical cannabis operations and infrastructure in Germany, a key market in Aphria’s international expansion. It is anticipated that the transaction will close in January 2019.
According to Aphria’s press release, “The transaction will bolster Aphria’s growing presence in Germany, which includes a three-pronged approach covering demand, supply and distribution. Earlier this year, the Company, through its wholly-owned subsidiary Aphria Deutschland (“Aphria Germany”), acquired a 25.1 percent interest in Berlin-based Schöneberg Hospital, providing access to both doctors and patients to support education about the benefits of medical cannabinoids. It was also the first step in Aphria Germany’s plans to build and operate pain treatment centers throughout Germany.”
Shares of Aphria traded as high as $13.14 on Thursday.
Emerald Health Therapeutics (EMHTF) (EMH) recently announced that it has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.
This comes on the heels of its previous announcement that it has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.
“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald’s filing of these patent applications is an important step,” said Chris Wagner, CEO of Emerald.
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Integrated Cannabis Company, Midam is being paid $25,000 per month for a period of 2 months beginning September 4, 2018, and ending March 9, 2019. This payment has been increased to $75,000 per month for the period of November 4 2018 and ending March 9, 2019. We own ZERO shares of Integrated Cannabis Company. We may buy or sell additional shares of (ICNAF)/(ICAN) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Integrated Cannabis Company. MarijuanaStocks.com, which is owned by MAPH Enterprises LLC., a Florida Corporation has been previously compensated $100,000 by a non-affiliate 3rd party for a 1 year period beginning August 1, 2017 and ending August 1, 2018 to publicly disseminate information about CNRP Mining, Inc. (CND.CN) (CRPGF) that is now Integrated Cannabis Company. Please click here for full disclaimer